熱門資訊> 正文
Ascendis因Yorvipath治疗甲状腺功能减退症获得FDA孤儿药地位
2024-09-12 06:07
- The FDA has granted Orphan Drug Designation to Ascendis Pharma (ASND) for its prodrug Yorvipath for the treatment of hypothyroidism in adults.
- Yorvipath is also known as palopegteriparatide and was developed as TransCon PTH. Palopegteriparatide originally received Orphan Drug Designation from the FDA in 2018.
More on Ascendis Pharma
- Ascendis Pharma Takes A Big Price Cut On Skytrofa
- Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript
- Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up
- Ascendis raised to outperform by Oppenheimer ahead of drug launch
- Ascendis stock falls 12% amid lowered outlook, royalty deal
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
